ccdc125 Antibody

What is CCDC125 and why are antibodies against it important for research?

CCDC125 (Coiled-coil domain-containing protein 125, also known as Kenae) is a protein involved in the regulation of cell migration through RhoGTPase activity modulation . Antibodies against CCDC125 are crucial research tools because they enable the detection, localization, and quantification of this protein in various experimental settings. Expression analysis has revealed that CCDC125 transcripts are highly expressed in tissues associated with the immune system, including the thymus, spleen, and bone marrow . This expression pattern suggests potential roles in immune function regulation.

The importance of CCDC125 antibodies in research stems from their ability to help elucidate the protein's role in both normal cellular processes and pathological conditions. For instance, studies have suggested possible connections between CCDC125 and movement disorders like Isaac's syndrome, as well as potential applications as biomarkers in cancer research . Anti-CCDC125 antibodies enable researchers to investigate these functions through various experimental techniques.

What are the recommended applications for CCDC125 antibodies in laboratory research?

CCDC125 antibodies can be utilized in multiple experimental techniques depending on research objectives. Based on validated applications, these antibodies are suitable for:

• Western blot (WB): For detecting CCDC125 protein in cell lysates and tissue homogenates, with recommended dilutions of approximately 1/250

• Immunohistochemistry on paraffin-embedded tissues (IHC-P): For visualizing protein localization in fixed tissues, typically used at 1/20 dilution

• Immunocytochemistry/Immunofluorescence (ICC/IF): For cellular localization studies using fixed and permeabilized cells, effective at concentrations around 4 μg/ml

The choice of application depends on whether you need to determine protein expression levels (WB), tissue localization patterns (IHC-P), or subcellular distribution (ICC/IF). When designing experiments, consider that some CCDC125 antibodies have been specifically validated with human samples, with predicted molecular weight of approximately 59 kDa for the target protein .

How should researchers validate the specificity of CCDC125 antibodies?

Validating antibody specificity is critical for ensuring reliable experimental results. For CCDC125 antibodies, a multi-step validation approach is recommended:

• Western blot verification: Compare the observed band pattern with the predicted molecular weight (approximately 59 kDa) . Use both positive control samples (tissues known to express CCDC125, such as human plasma, liver, or tonsil) and negative controls.

• Blocking peptide competition: Pre-incubate the antibody with the immunogen peptide (for example, recombinant fragment within Human CCDC125 aa 200-350) before application to samples. Specific binding should be significantly reduced or eliminated.

• Cross-reactivity assessment: When working with non-human samples, examine sequence homology between species and verify cross-reactivity experimentally.

• Multiple antibody comparison: When possible, use two different antibodies targeting distinct epitopes of CCDC125 to confirm specificity.

• Knockdown/knockout controls: If available, use CCDC125 knockdown or knockout cell lines as negative controls to confirm antibody specificity.

Antibody validation is particularly important when moving to new experimental systems or when quantitative measurements are required for downstream analysis.

How can CCDC125 antibodies be utilized to investigate cell motility mechanisms?

CCDC125 has been demonstrated to regulate cell motility through modulation of RhoGTPase activity (RhoA, Rac1, and cdc42) . To investigate these mechanisms using CCDC125 antibodies, researchers can implement the following methodological approaches:

• Co-immunoprecipitation (Co-IP) studies: Use CCDC125 antibodies to pull down protein complexes and analyze interacting partners, particularly RhoGTPases and their regulators. This helps identify the molecular components of CCDC125-mediated signaling pathways.

• Live-cell imaging with immunofluorescence: Combine CCDC125 antibody staining (ICC/IF) with time-lapse microscopy to correlate CCDC125 localization with dynamic cellular processes during migration.

• RhoGTPase activity assays: Correlate CCDC125 expression levels (detected via western blotting) with RhoGTPase activity in response to various extracellular stimuli. Studies have shown that cells stably expressing CCDC125 exhibit delayed cell motility and deregulated RhoGTPase activity .

• Wound healing assays: Measure cell migration rates in scratch assays while monitoring CCDC125 localization and expression using appropriate antibodies. This approach can help establish the functional relationship between CCDC125 levels and migration capacity.

• Phosphorylation status analysis: Use phospho-specific antibodies alongside CCDC125 antibodies to investigate post-translational modifications that might regulate its activity in the cell motility pathway.

By implementing these approaches, researchers can dissect the molecular mechanisms through which CCDC125 influences cell migration, potentially revealing new therapeutic targets for conditions characterized by aberrant cell motility.

What methodological considerations should be addressed when using CCDC125 antibodies in cancer research?

When utilizing CCDC125 antibodies in cancer research, several methodological considerations should be addressed:

• Sample preparation optimization: Different cancer tissues may require specific fixation and antigen retrieval protocols. For example, when examining CCDC125 in colon tissue, paraffin-embedded samples have been successfully used with immunohistochemistry at 1/20 dilution .

• Expression level quantification: For accurate comparison between normal and cancerous tissues, standardized quantification methods are essential. Western blot analysis using CCDC125 antibodies can be performed at 1/250 dilution, with appropriate loading controls and normalization protocols .

• Biomarker potential assessment: Recent studies have investigated serum CCDC25 levels as potential biomarkers for various cancers. When analyzing serum samples:

  • Consider appropriate dilution factors (e.g., 1:3 dilution for samples with high expression)

  • Use recombinant CCDC25 protein to establish standard curves (0.0156-0.5 ng/μl range)

  • Include appropriate normalization controls (pooled samples) for reliable quantification

• Cross-cancer comparison: Different cancer types show varying CCDC25 expression patterns. ROC analysis has revealed that serum CCDC25 can distinguish:

  • Cholangiocarcinoma from healthy controls with 100% sensitivity and specificity

  • Colorectal cancer with 68% sensitivity and 100% specificity

  • Breast cancer with 88% sensitivity and 100% specificity

  • Hepatocellular carcinoma with 98% sensitivity and 100% specificity

• Antibody selection for circulating vs. cell-associated detection: When studying both tissue and circulating CCDC125, consider antibodies with appropriate epitope specificity, as some antibodies may show differential recognition of shed versus cell-associated antigens (similar to issues observed with CA 125 antibodies) .

What are optimal protocols for using CCDC125 antibodies in immunofluorescence studies?

For optimal results in immunofluorescence studies using CCDC125 antibodies, the following protocol recommendations should be considered:

• Cell preparation and fixation:

  • Fix cells with 4% paraformaldehyde (PFA) for 15-20 minutes at room temperature

  • Permeabilize with 0.1% Triton X-100 for 5-10 minutes

  • For adherent cell lines like U2OS cells, grow on coverslips prior to fixation

• Antibody incubation parameters:

  • Block with 1-5% BSA in PBS for 30-60 minutes

  • Use CCDC125 antibody at approximately 4 μg/ml concentration

  • Incubate primary antibody overnight at 4°C or for 1-2 hours at room temperature

  • Use fluorophore-conjugated secondary antibodies at 1:500-1:2000 dilution, incubating for 1 hour at room temperature

• Controls and counterstaining:

  • Include negative controls (secondary antibody only)

  • Use nuclear counterstain (e.g., DAPI) for reference

  • Consider co-staining with cytoskeletal markers (e.g., actin) given CCDC125's role in cell motility

• Imaging considerations:

  • Capture Z-stack images to fully assess subcellular localization

  • Use consistent exposure settings across experimental conditions

  • Consider confocal microscopy for high-resolution subcellular localization

• Data analysis approach:

  • Quantify fluorescence intensity relative to control samples

  • Assess colocalization with relevant markers (e.g., cytoskeletal proteins, RhoGTPases)

  • Perform subcellular distribution analysis using line scan profiles

These protocols have been shown to effectively detect CCDC125 in PFA/Triton X-100 fixed and permeabilized cells, producing specific green fluorescence signal corresponding to CCDC125 localization .

How can researchers address non-specific binding issues when working with CCDC125 antibodies?

Non-specific binding can significantly compromise experimental results when working with CCDC125 antibodies. To address this issue, researchers should implement the following methodological strategies:

• Optimize antibody dilution: Titrate the antibody concentration to determine the optimal working dilution that maximizes specific signal while minimizing background. For Western blotting, 1/250 dilution has been validated for CCDC125 antibodies , but this may need adjustment based on specific experimental conditions.

• Enhance blocking protocols:

  • For Western blots: Use 5% non-fat dry milk or BSA in TBST, blocking for at least 1 hour

  • For IHC/ICC: Consider longer blocking times (2+ hours) with 5-10% normal serum from the species in which the secondary antibody was raised

• Validate with multiple detection methods: Confirm findings using different techniques (e.g., if seeing unexpected results in IHC, verify with Western blot analysis). CCDC125 antibodies have been validated for multiple applications including WB, IHC-P, and ICC/IF .

• Include appropriate controls:

  • Negative controls (no primary antibody)

  • Isotype controls (irrelevant antibody of the same isotype)

  • Peptide competition (pre-incubation with immunizing peptide)

  • Use tissues/cell lines with known CCDC125 expression profiles (e.g., human plasma, liver, tonsil, colon)

• Modify washing procedures:

  • Increase the number of washes

  • Extend washing duration

  • Use detergent-containing buffers (0.1-0.3% Tween-20 or Triton X-100)

• Consider sample-specific adjustments: Different sample types may require specific optimization. For example, when working with paraffin-embedded tissues, antigen retrieval methods may need modification to reduce background while maintaining specific signal .

What are effective strategies for optimizing CCDC125 detection in western blotting experiments?

For optimal detection of CCDC125 in western blotting experiments, researchers should consider the following methodological strategies:

• Sample preparation optimization:

  • For cell lysates: Use RIPA buffer supplemented with protease inhibitors

  • For tissue samples: Homogenize in appropriate buffer (e.g., RIPA) at 4°C

  • Determine optimal protein loading amount (typically 20-50 μg total protein)

• Gel electrophoresis parameters:

  • Use 10-12% SDS-PAGE gels for optimal resolution of CCDC125 (predicted MW: 59 kDa)

  • Run samples at constant voltage (150V) for approximately 90 minutes

• Transfer and detection optimization:

  • Use PVDF membranes for protein transfer

  • Transfer at 100V for 60-90 minutes or overnight at 30V (4°C)

  • Block membranes with 5% non-fat dry milk or BSA in TBST

  • Use CCDC125 antibody at 1/250 dilution

  • Incubate with primary antibody overnight at 4°C

  • Use HRP-conjugated secondary antibodies with ECL detection system

• Signal verification approaches:

  • Confirm band size against molecular weight markers (expected: 59 kDa)

  • Include positive control lysates known to express CCDC125 (e.g., RT4, U251 MG, human plasma, liver, or tonsil lysates)

  • If multiple bands appear, verify specificity through additional validation experiments

• Quantification considerations:

  • Use appropriate normalization controls (β-actin, GAPDH)

  • Employ densitometry software for quantitative analysis

  • Perform experiments in at least triplicate for statistical validity

Following these protocols, CCDC125 has been successfully detected in various human samples, including cell lines (RT4, U251 MG) and tissues (plasma, liver, tonsil), confirming the utility of these approaches for reliable protein detection .

How are CCDC125 antibodies contributing to our understanding of RhoGTPase signaling in disease models?

CCDC125 antibodies are advancing our understanding of RhoGTPase signaling pathways in various disease contexts through several innovative research approaches:

• Mechanistic studies of cell motility disorders: Research has established that CCDC125 (Kenae) regulates cell motility through modulation of RhoGTPase activity (RhoA, Rac1, and cdc42) . When cells stably express CCDC125, they exhibit delayed motility and deregulated RhoGTPase responses to extracellular stimuli . CCDC125 antibodies enable researchers to:

  • Track protein expression and localization during migration events

  • Correlate CCDC125 levels with RhoGTPase activation states

  • Identify potential interaction partners in signaling cascades

• Neurological disorder investigations: Isaac's syndrome, a movement disorder characterized by peripheral motor nerve hyperexcitability, has been linked to CCDC125 . While some patients develop auto-antibodies to voltage-gated potassium channels (VGKCs), not all cases show this pattern, suggesting alternative mechanisms . CCDC125 antibodies help researchers:

  • Examine potential autoimmune responses against CCDC125

  • Investigate neuronal expression patterns in disease models

  • Assess functional consequences of altered CCDC125 expression in neuronal cells

• Cancer research applications: Studies have investigated CCDC25 as a potential biomarker for various cancers, including cholangiocarcinoma, colorectal cancer, breast cancer, and hepatocellular carcinoma . CCDC125 antibodies facilitate:

  • Quantitative assessment of expression in tumor vs. normal tissues

  • Evaluation of RhoGTPase pathway alterations in cancer progression

  • Development of diagnostic tools based on detecting serum CCDC25 levels

• Immune system regulation studies: Given CCDC125's high expression in immune-related tissues (thymus, spleen, bone marrow) , antibodies against this protein help researchers:

  • Characterize expression patterns in specific immune cell populations

  • Investigate potential roles in immune cell migration and function

  • Examine possible connections to autoimmune disorders

These research directions highlight how CCDC125 antibodies are instrumental in elucidating the complex roles of RhoGTPase signaling in both normal physiology and pathological conditions.

What are the latest findings regarding CCDC125 as a potential biomarker for cancer detection?

Recent research has revealed promising findings regarding CCDC125/CCDC25's potential as a cancer biomarker, particularly for detecting and differentiating various cancer types:

• Serum CCDC25 in multiple cancer types: Quantitative analysis of serum CCDC25 levels has demonstrated significant diagnostic potential across several cancer types. Using dot blot assays with anti-CCDC25 antibodies, researchers have established:

  Cancer Type	Sensitivity	Specificity	AUC	Cut-off Value
  Cholangiocarcinoma (CCA)	100%	100%	1.000	0.017 ng/μl
  Colorectal Cancer (CRC)	68%	100%	0.850	0.017 ng/μl
  Breast Cancer (BC)	88%	100%	0.961	0.017 ng/μl
  Hepatocellular Carcinoma (HCC)	98%	100%	0.992	0.017 ng/μl

  These findings suggest that serum CCDC25 detection using specific antibodies could serve as a valuable diagnostic tool, particularly for cholangiocarcinoma and hepatocellular carcinoma .

• Methodological advances in detection: Researchers have refined techniques for CCDC25 detection in serum samples using:

  • Western blot validation with rabbit polyclonal antibodies against human CCDC25

  • Quantitative dot blot assays using chemiluminescent detection systems

  • Standardization with recombinant CCDC25 protein to generate standard curves

• Differential expression patterns: Bioinformatic analyses using databases such as the Human Protein Atlas and Gene Expression Profiling Interactive Analysis 2 (GEPIA2) have revealed distinct CCDC25 expression patterns across various cancer and normal tissues , providing context for interpreting serum biomarker data.

• Sample preparation considerations: Research has established that different cancer types may require specific sample preparation approaches:

  • CCA samples often require dilution (1:3) due to very high CCDC25 levels

  • Other cancer samples (CRC, BC, HCC) can typically be analyzed as neat sera

These findings indicate that CCDC125/CCDC25 antibody-based detection methods hold significant promise for cancer diagnostics, particularly when incorporating appropriate methodological controls and standardization approaches.

What approaches can researchers use to develop improved CCDC125 antibodies for specialized applications?

For researchers seeking to develop enhanced CCDC125 antibodies with specialized functionalities, several advanced approaches can be considered:

• Epitope-specific antibody generation: Targeting specific regions of CCDC125 can yield antibodies with enhanced properties for particular applications:

  • Focus on the C-terminal region (aa 200-350) that has been successfully used as an immunogen

  • Target regions predicted to be involved in protein-protein interactions, particularly those implicated in RhoGTPase regulation

  • Consider regions that might distinguish between different conformational states of CCDC125

• Single-chain fragment variable (scFv) development: Lessons from other antibody engineering efforts suggest that scFv development could enhance CCDC125 antibody functionality:

  • Select optimal linker peptides (such as (Gly4Ser)3) based on bioinformatic stability predictions

  • Use molecular dynamics simulation to compare structural stability of different constructs

  • Validate binding properties through molecular docking and ELISA

• Cell association selectivity optimization: Drawing from approaches used with other antibodies (like anti-CA 125), researchers can develop CCDC125 antibodies with enhanced selectivity for cell-associated forms:

  • Target membrane-proximal regions that might be absent in shed forms

  • Characterize binding affinities (KD <5 nM would be desirable for high-affinity antibodies)

  • Test selectivity ratio between cell-associated and circulating forms

• Expression system optimization for recombinant antibodies:

  • Bacterial expression systems like E. coli BL21 (DE3) can be used with appropriate induction methods (IPTG or lactose)

  • Consider periplasmic expression for proper folding of antibody fragments

  • Validate functionality through multiple detection methods (SDS-PAGE, Western blot, ELISA)

• Application-specific modifications:

  • For imaging applications: Develop directly conjugated fluorophore-antibody complexes

  • For therapeutic potential: Explore humanization of promising antibody candidates

  • For quantitative assays: Focus on antibodies with linear dose-response characteristics

By implementing these approaches, researchers can develop next-generation CCDC125 antibodies with enhanced properties for specific research and potential diagnostic applications.